Author

F. Campbell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1 Approach:mechanistic / dynamical model· 1

Frequent Co-Authors

A. Mielgo· 2 shared M. Schmid· 2 shared A. Saeed· 1 shared A. Santos· 1 shared A. Taylor· 1 shared C. Figueiredo· 1 shared C. Rainer· 1 shared D. Engle· 1 shared

Activity by Year

2017-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Mielgo

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Customizable, engineered substrates for rapid screening of cellular cues

E. Huethorst, M. Cutiongco, F. Campbell, A. Saeed, R. Love, P. Reynolds, M. Dalby, N. Gadegaard

The paper introduces a customizable multiwell array for high-throughput screening of biophysical cues, demonstrating its effectiveness in assessing cell responses to topography and rigidity.

bioRxiv · Jul 5, 2019Bioengineering

Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer

V. Quaranta, C. Rainer, S. R. Nielsen, M. Raymant, M. S. Ahmed, D. Engle, A. Taylor, T. Murray, F. Campbell, D. Palmer, D. Tuveson, A. Mielgo, M. Schmid

This study shows that macrophage-derived granulin promotes resistance to immune checkpoint inhibitors in metastatic pancreatic cancer by excluding CD8+ T cells, and blocking granulin improves anti-tumor immunity.

bioRxiv · Dec 15, 2017Cancer Biology

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.

L. Ireland, A. Santos, F. Campbell, C. Figueiredo, L. Ellies, U. Weyer-Czernilofsky, T. Bogenrieder, M. Schmid, A. Mielgo

This study shows that blocking insulin-like growth factors enhances paclitaxel's effectiveness against metastatic breast cancer by reducing tumor growth and lung metastasis in pre-clinical models.

bioRxiv · Jul 23, 2017Cancer Biology